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Privacy in Genetics Research 
stringent regulations to protect experimen-
tal research data from third-party access. 
(Recommendation 1.) 
Unlike clinically validated medical in-
formation obtained for patient care, exper-
imental research data often lack analytical 
and clinical validity. This means that re-
search data may be clinicaily meaningless 
or misleading. Research studies to identify 
the genetic basis of a specific disease may 
generate very preliminary, inconclusive, or 
invalid experimental information linking a 
genetic alteration with risk of developing 
the disease. Unless a research protocol in-
cludes the clinical care of the research par-
ticipant, experimental research data should 
be kept in the researcher's scientific files 
and not placed in the participant's medical 
record (11). (Recommendation 2.) 
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Rapid progress in the Human Genome Project has heightened public aware-ness of the positive impact of genet-
ics research on human health. Along with 
these positive effects have come concerns 
about who will have access to personal ge-
netic information and how it will be used. 
Here, we present policy recommendations 
(see the table) for protecting the privacy of 
genetic information in research (1). 
A particular person's genetic informa-
tion may be of interest to a wide variety of 
individuals and organizations. Insurers 
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and employers may 
want to use it as a 
predictor of future 
illness, health-care 
costs, or the ability 
to perform a job. 
Family members, 
educational institutions, or the courts (in 
cases where custody is being challenged, 
for example) may also want access to ge-
netic information. Indeed, genetic infor-
mation has already been used to deny 
medical benefits to retirees with illnesses 
with a known genetic basis (2). Cases of 
insurance and employment discrimination 
based on genetic information have also 
been reported (3). 
Recommendations to restrict use of ge-
netic information in health insurance and in 
the workplace have been developed by the 
National Action Plan on Breast Cancer 
(NAPBC) and the National Human Genome 
Research Institute (NHGRI) ( 4). State and 
federal laws restrict some uses of genetic in-
formation in health insurance and the work-
place (5. 6). Nevertheless, comprehensive 
federal protections are not in place (7). 
The privacy of medical information is 
protected principally by state law, although 
the level of protection varies widely from 
state to state. These laws· generally restrict 
access to health-care records to those with 
signed authorizations or a court order, or 
in other limited circumstances. 
The Federal Privacy Act of 1974 safe-
guards health, research, and other records 
held by federal agencies. Nevertheless, 
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there are many instances in which disclo-
sures without the consent of the individual 
are allowable. Other than federal statutes to 
protect research specific to crimes, health-
care outcomes, or medical liability, there 
are no comprehensive federal laws to pro-
tect the privacy of research information (8). 
Currently, the U.S. Congress is consid-
ering measures to protect the privacy and 
confidentiality of individually identifiable 
health information (9). Pending legislation 
addresses the responsibilities of individu-
als and organizations who maintain health 
information, describes who can have ac-
cess to individual medical records, and 
outlines the process for obtaining access. 
Of concern to the scientific community 
is the danger that experimental research 
records might be included inappropriately 
in the broad definitions of individually 
identifiable health information (1 0). Al-
though it may seem paradoxical, inclusion 
of these records could allow unnecessary 
and inappropriate third-party access to this 
information (such as by law enforcement 
officials or courts). The social value of re-
search, the altruistic nature of research 
participation, and the reliance of the re-
search enterprise on volunteers necessitate 
Individuals who participate in research 
are protected by the Common Rule (12), 
which requires that all research with hu-
man subjects that is supported, conducted, 
or regulated by federal agencies must be 
reviewed by an institutional review board 
(IRB). IRBs are responsible for ensuring 
that the participants' consent is informed 
and voluntary, that risks to the participants 
are minimized, and that the participants' 
rights and welfare are protected. IRBs also 
consider whether the proposed informed 
consent document includes "a statement 
describing the extent, if any, to which con-
fidentiality of records identifying the sub-
ject will be maintained" (13). The IRB 
guidebook recommends that data should 
not be released except as authorized by the 
research subject and that subsequent re-
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quests for information should be subject to 
the agreements in the informed consent 
(14). However, current practices are di-
verse, and there are no specific mandates 
or requirements for even the most basic 
levels of privacy and confidentiality pro-
tections. (Recommendation 3.) 
The public focus has been on privacy of 
information acquired in the clinical setting 
(15); privacy of experimental research data 
has received comparably little attention. 
There has been no systematic analysis of 
methodologies used to protect privacy of 
research records or of breaches of confi-
dentiality. An assessment of current prac-
tices and development of best practices to 
protect research data from third-party ac-
cess is needed. (Recommendation 4.) 
As early as 1977, the Federal Privacy 
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ically meaningless or misleading, thus 
lacking the clinical and analytical validity 
of medical records (21). 
In a specific case, 5209 people were re-
cruited to participate in a longitudinal study 
of factors that contribute to cardiovascular 
disease (22). Subsequently, the study en-
rolled another 5124 adult children and 
spouses of the original group. The subjects 
gave permission for genetic studies, the col-
lection of medical histories, and physical 
examinations. Tests were performed in a re-
search laboratory that can tolerate a l to 2% 
error rate that would not be tolerated in a 
clinical laboratory because the study was 
evaluating the significance of genetic vari-
ants among thousands of persons, not the 
relevance to one individual. 
Concern about sample 
Protection Study Com-
mission strongly favored 
"statutory immunity which 
protects the rights and in-
terests of the individual" 
research participant (16). 
The Public Health Service 
Act provides for Certifi-
cates of Confidentiality 
(17) that protect personal-
ly identifiable research in-
formation. These certifi-
cates can be obtained by 
privately funded as well 
as federally funded re-
search projects of a sensi-
tive nature, including pro-
jects involving informa-
tion that "could reason-
ably lead to social stigma-
tization or discrimination" 
(18). They provide a legal 
defense for researchers 
against compelled disclo-
"Experime~ 
research data 
integrity as well as ana-
lytical and clinical validi-
ty of medical tests pro-
vides the basis for a fed-
eral law (CLIA) that re-
quires laboratories pro-
viding data back to pa-
tients to meet a number 
of quality standards (23). 
Many research laborato-
ries are not CLIA ap-
proved. Consequently, 
there is concern that 
transmitting the outcome 
of these studies to the re-
search participants would 
result in the transmission 
of false-positive or false-
negative results. 
should be kept 
in the 
researcher's 
scientific files 
and not placed 
in the 
participant's I medical record." Providing such data to subjects may entail sig-
nificant risks and cause 
erroneous conclusions to 
be made that could result 
sure of identifiable research information as 
a result of a subpoena or court order (19) 
and can be a critical device for the protec-
tion of genetic research data (20). Howev-
er, they do not provide legal protection for 
research participants from compelled dis-
closure. (Recommendation 5.) 
It is universally accepted that individu-
als should have access to their own medi-
cal information. At first examination, it 
seems straightforward to conclude that this 
should apply to experimental research da-
ta. There are several key characteristics, 
however, that differentiate medical infor-
mation from experimental research data. 
Unlike medical records, research records 
contain experimental data and analyses 
necessary to test hypotheses. The clinical 
significance of the results of a particular 
experiment may only be established after 
many years of additional research, if ever. 
This means that research data may be clin-
in physical, psychosocial, or economic 
harms. If genetic research results are to be 
given to the subjects, the protocol must 
provide for counseling before and after the 
test (24). For a study with about l 0,000 
participants, the cost of counseling is esti-
mated to be more than $500,000 per year. 
Although this cost is warranted in studies 
that generate data useful to individual par-
ticipants, in the case described above the 
expenditure may be unwarranted. If a poli-
cy mandating return of clinically meaning-
less data were implemented, associated 
costs and personnel might provide an ob-
stacle to doing the study. Thus, in the ab-
sence of clinical validity there should not 
be an absolute requirement for data to be 
returned to subjects. For research in which 
data are not provided to subjects, the re-
searcher should demonstrate absence of 
clinical validity, an IRB should be required 
to review and approve the exception, and 
the informed consent document should 
state explicitly that the data will not be re-
turned to the research subject. (Recom-
mendation 6.) 
Implementation of our recommend-
ations is imperative to maintain the trust 
placed in the research process and to real-
ize the potential of genetics research to 
benefit human health. 
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